Drugs / ABM-168
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05831995 | Mar 2023 → Jun 2024 | neoplasm | ABM Therapeutics Corporation | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABM-168 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05831995 ↗ |
| Route | Oral | “Dosage: 0.5 mg; 2 mg; 6 mg; once daily by oral administration” NCT05831995 ↗ |